Lipid OC7|long-acting saRNA therapies|DC Chemicals

Cas No.:
Chemical Name:	Lipid OC7
Synonyms:	Lipid-OC7;LipidOC7
SMILES:	CCCCCCCC/C=C\CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC/C=C\CCCCCCCC)CCC(=O)OCCN1CCCCCC1
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC68020	Lipid OC7	Lipid OC7, as described in the patent WO2022207938A1, is a novel ionizable lipid that serves as the core functional component of the saNppa-LNP delivery system. Its key innovation lies in its unique biodegradable structure featuring an internal ester bond. Under typical physiological conditions, this bond hydrolyzes, triggering a charge shift from a cationic form that complexes nucleic acids to a zwitterionic form that releases them. This property is central to its role in enabling long-acting self-amplifying RNA (saRNA) therapies. Specifically, OC7 facilitates immune stealth by mitigating early interferon responses, supports sustained and efficient intracellular replication of saRNA even at low doses, and enables therapeutic protein expression that persists for over 28 days from a single administration. This combination of efficient delivery, controlled release, and extended duration of action makes OC7-based LNPs a promising platform for long-term treatments, such as for myocardial infarction, as demonstrated in the referenced research.
DC67988	KT-001	KT-001 is a novel ionizable cationic lipid developed by Vivas, Inc., disclosed in US 2026/0007612 A1 (published Jan 8, 2026).KT-001 demonstrates exceptional skeletal muscle targeting and low liver toxicity.Unlike traditional lipids that primarily accumulate in the liver, KT-001 avoids serum ApoE binding, preventing hepatic uptake. Upon intramuscular injection, it achieves a 29-fold reduction in liver off-target expression compared to standard lipids, while maintaining robust, long-lasting protein expression at the injection site.Its optimized pKa enables precise, pH-responsive endosomal escape for high transfection efficiency. KT-001 is an ideal carrier for localized mRNA vaccines and targeted therapeutics for muscle-related disorders.